AMP Europe 2023 is proud to announce the following sponsors:
-
Agena Bioscience
Agena Bioscience
Agena Bioscience
Industry Symposium – Monday, June 19, 9:45
liquid Biopsies in clinical practice – Identification of therapeutically relevant mutations at baseline in plasma-derived cell free DNA in patients with metastasized NSCLC to assist in treatment decision making
Ed SchuuringProf. Ed Schuuring studied Medical Biology at the University of Amsterdam (cum laude). He worked as a staff clinical scientist in Molecular Pathology at Leiden University Medical Center (1991-2000). He continued his carrier at the Department of Pathology at the University Medical Center Groningen, chairs the Laboratory of Molecular Pathology and is full professor in “Molecular Oncological Pathology”. His main research interests are the identification and implementation of diagnostic molecular tumor markers associated with early detection, treatment-decision-making, MRD, response monitoring and resistance to TKI-/immunotherapy in cervical cancer, GIST, NEN and NSCLC in tissue-biopsies and cell-free plasma. He is a senior member of the Dutch Society of Pathology (NVVP), AACR, AMP, ESP, ASCO, steering committee-member of the NVVP section Clinical, Molecular and Experimental Pathology, of COIN, ESP/QuIP and ELBS, and consultant in (inter)national committees and advisory boards on Molecular Pathology.
-
AstraZeneca UK Ltd
AstraZeneca UK Ltd
AstraZeneca UK Ltd
Industry Symposium – Sunday, June 18, 12:15
Keeping pace with the homologous recombination deficiency testing landscape
Pantelis Constantoulakis
Professor Attard Gert
Professor Giuseppe Viale (Chair)
Industry Symposium – Sunday, June 18, 15:45
If tissue is the issue, is liquid biopsy the answer for NSCLC biomarker testing?
Fernando Lopez-Rios
“12 de Octubre” University HospitalFernando Lopez-Rios has recently joined the Department of Pathology at “12 de Octubre” University Hospital (Madrid) as the Chief of the Molecular Diagnostics Service. He received his medical degree and PhD from the Faculty of Medicine at Autonoma University and Complutense University respectively and completed his residency in Pathology at “12 de Octubre” University Hospital (Madrid). Dr Lopez-Rios has also been the Director of the Therapeutic Targets Laboratory at “HM Hospitales” and a visiting researcher at Memorial Sloan Kettering Cancer Center (New York). His main clinical and research expertise is in cancer biomarker testing, with a special interest in lung cancer and mesothelioma. He is currently a member of the IASLC Pathology Committee.
Lukas Bubendorf
Institute of Pathology, University Hospital BaselProfessor Lukas Bubendorf is a board-certified Surgical Pathologist and Cytopathologist. He is a Professor of Pathology and the Head of Cytopathology in the Institute for Pathology at the University Hospital Basel, Basel, Switzerland which provides highly specialised diagnostic services. Professor Bubendorf’s research focuses on lung and urogenital cancer and in particular on the analysis of molecular testing and the genomic evolution of tumours. He won the Maurice Goldblatt Award in 2015 for his research in the development, testing and introduction of novel and modern techniques for clinical practice in all aspects of cytology. He also received the Fred R. Hirsch Lectureship Award for Translational Research by IASLC in 2022. He is currently a member of the IASLC Pathology Committee.
-
Beckman Coulter Life Sciences
Beckman Coulter Life Sciences
-
Bionano
Bionano
-
College of American Pathologists
College of American Pathologists
-
Golden Helix, Inc.
Golden Helix, Inc.
Industry Symposium – Monday, June 19, 13:00
Achieving Economic Success as an NGS Lab: Strategy and Implementation
Andreas Scherer, PhD
President and CEO at Golden Helix Inc -
Horizon Discovery Ltd
Horizon Discovery Ltd
-
Ikonisys
Ikonisys
-
Invivoscribe
Invivoscribe
Invivoscribe
Industry Symposium – Tuesday, June 20, 09:45
Application of Massively Parallel Sequencing in B-cell MRD Detection
Dr. Linda Lee, PhDDr. Linda Lee is the Senior scientist for molecular haematology at Royal North Shore Hospital in Sydney Australia. She has academic and clinical trial experience prior to joining the pathology sector. The current laboratory she leads became the first in the country as an ERIC IG Certified centre that offers IG / TCR clonality analysis and MRD detection by NGS under NATA accreditation. Currently, Dr. Linda Lee is developing the laboratory into a MRD reference testing facility for haematological disorders.
Optimizing Molecular Minimal Residual Disease Analysis in Adult Acute Lymphoblastic Leukemia
Dr. Irene Della StarzaDr. Irene Della Starza obtained a degree in Biological Sciences from the University of Urbino in Italy. She then continued her education and graduated with a Masters in Cytogenetics and Cytogenomics from the University of Rome, Tor Vergata and a PhD in Hematological Sciences from the University of Rome, Sapienza where she later also did her Postdoctoral Fellowship in Hematology. She then began working as a Specialist in Clinical Pathology and Clinical Biochemistry at the University of Rome, Sapienza. She has been working for many years in the Section of Hematology of the Umberto, General Hospital, dealing with acute and chronic lymphoproliferative disorders both from a healthcare and research point of view. She has authored or co-authored 56 publications and has a particular interest in the identification of molecular target disease-related immunoglobulin (IG), T-cell receptor (TCR) gene rearrangements, and t(14;18) IgH/BCL2 and t(11;14) BCL1/IgH translocation genes for clonality analysis and for monitoring of measurable residual disease (MRD). -
Labcorp
Labcorp
Labcorp
Industry Symposium – Monday, June 19, 09:45
Novel insights in tumour genomic profiling: How to expand precision cancer medicine in the real world
Nicole Pfarr
Institute of Pathology at the Technical University of MunichFicole Pfarr is the Head of Molecular Diagnostics at the Institute of Pathology at the Technical University of Munich and also Head of the Next Generation Sequencing facility. After starting her research work at the Johannes Gutenberg University of Mainz (Germany) working in the field of congenital human genetic diseases in children, she moved to Heidelberg in 2009 to work at the Thorax clinic of the University Hospital Heidelberg in the field of pulmonary arterial hypertension. In 2013, she joined the team of Professor Wilko Weichert at the Institute of Pathology in Heidelberg. There, she helped integrate the technique of next generation sequencing into the molecular pathology diagnostic laboratory. In 2015, she started working at the Technical University of Munich in her current positions. In 2021, she was announced as one of the chairs of the German Working Group for Molecular Pathology. Until now, she published more than 100 articles mainly in the field of cancer.
Patrick Hollender
EU for Personal Genome DiagnosticsPatrick is graduate from Fac. Pharmacy (Reims, France) with a Doctoral Degree in Molecular Biology & Pharmacology. He has a long track record of successful commercial experience in the Research, Molecular Genomics, Next Generation Sequencing (NGS) and Clinical Oncology fieldsover the past 20 years.
Patrick’s personal drivers have always been linked to the personalized medicine revolution, focusing on patient care by democratizing access to innovative and disruptive genomic solutions: “The right diagnostic, at the right time, with the right tools, for the right patient, with the right samples”.
For serving this, he has worked for market leaders in the healthcare and medical technologies industry as Invitrogen, ThermoFisher and Illumina in various roles such as sales, operations, projects, partnerships and sales team management across France and more broadly in EMEA region, in direct or indirect sales channels.
He has joined PGDx as an International Sales Director in August 2021 with a key and major focus on EU markets. PGDx was subsequently acquired by Labcorp in February 2022.
He’s actual primary responsibility is to achieve the commercial company goals by deploying a successful EU commercial strategy for distributed kitted assays and service solutions from PGDx.
He also set-up and drive strategic initiatives and partnerships with key business stakeholders from this industry by leveraging multidisciplinary Labcorp teams and resources.
Freddie Sharkey
EMEA/APACFreddie has a PhD in Molecular Genetics and trained as a HPC Registered Clinical Scientist in Molecular Genetics within the NHS. He has spent his entire career, spanning over 20 years, in clinical diagnostics, both directly within the healthcare and medical technologies sectors. The core personal objective & aim has always been to improve patient care through unlocking access to innovative and disruptive genomics technologies that can provide greater insights into disease and patient management.
During his career, Freddie has built, lead and developed multiple large, profitable business units, primarily across the EMEA and APAC regions. He has held numerous senior leadership and executive roles with large multinational medical technology organizations including Life Technologies, Thermo Fisher and Illumina. Freddie was Chief Commercial Officer & Head of Oncology at Congenica, a UK based AI organization, prior to joining Personal Genome Diagnostics (PGDx) in 2021. PGDx was subsequently acquired by Labcorp in February 2022. Freddie has also advised various SMEs in the Genomics / Bioinformatics / AI space, together with similar roles with strategic Global Investment organizations, so has a rounded view on the current genomics market.He is currently the Senior Director, and Head of Commercial EMEA & APAC regions for PGDx where his focus is on developing an organization that can scale and provide global decentralized end-to-end solutions in Next Generation Sequencing (NGS) to global healthcare sectors, while also leveraging the extensive Labcorp infrastructure and array of clinical solutions. -
LGC
LGC
LGC Biosearch Technologies and LGC Clinical Diagnostics provide mission critical components for genomics and a comprehensive quality measurement tools portfolio to complement the development pipeline from concept through commercialisation across a variety of disciplines, including clinical genomics, molecular diagnostics, serology, immunochemistry and clinical chemistry. With over 180 years of industry expertise, LGC is a trusted supplier of technologies to IVD and biopharmaceutical developers, Contract Research Organizations, and academic institutions helping them achieve accurate and reliable diagnostic results. Our FDA-registered and ISO-certified facilities ensure the quality and compliance our customers need to succeed.
-
N Gene Bio
N Gene Bio
-
OncoDNA Group
OncoDNA Group
-
Oxford Nanopore Technologies
Oxford Nanopore Technologies
-
Pillar Biosciences, Inc
Pillar Biosciences, Inc
-
Promega Corporation
Promega Corporation
-
SeqOne
SeqOne
SeqOne
Industry Symposium – Tuesday, June 20, 12:45
A clinical genomics platform to analyse somatic alterations : point of view of a molecular pathologist
Michaël Blum
Head of Research and Development for SeqOne
Pierre-Jean Lamy
Molecular pathologist -
Sophia Genetics
Sophia Genetics
-
Standard BioTools
Standard BioTools
Standard BioTools
Industry Symposium – Monday, June 19, 13:00
Towards a Deep Imaging and Omics-Based Tumor Microenvironment Characterization within the IMMUcan Consortium
Daniel Schulz
University of ZurichAfter studying technical biology at the University of Stuttgart, in 2009 Daniel moved to the lab of Patrick Cramer at the Ludwig-Maximilians University of Munich for his PhD. Together with colleagues he developed and applied whole transcriptome nascent RNAseq methods to investigate genome wide mechanisms of transcription regulation. For his postdoc Daniel was rewarded an EMBO long-term fellowship joining the lab of Bernd Bodenmiller at the University of Zurich. There, he set out to develop assays for RNA and protein co-detection using suspension and imaging mass cytometry investigating the tumor micro environment. Since 2019 Daniel leads the IMMUcan project within the Bodenmiller lab. This consortium aims at the characterization of the tumor microenvironment of more than 3000 cancer patients using whole exome sequencing, RNAseq, whole slide fluorescence imaging and imaging mass cytometry.
-
STEMCELL Technologies
STEMCELL Technologies
